Affitech’s collaboration partner IBC Generium submits Clinical Trial Application in Russia for AT001/r84
December 30, 2011 08:21 ET
|
Affitech A/S
Copenhagen and Oslo, 2011-12-30 14:21 CET (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced that its Russian collaboration partner, IBC Generium,...
Affitechs samarbejdspartner IBC Generium indsender ansøgning i Rusland om tilladelse til at starte kliniske forsøg med AT001/r84
December 30, 2011 08:21 ET
|
Affitech A/S
København og Oslo, 2011-12-30 14:21 CET (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), der udvikler antistoflægemidler, meddeler i dag, at Selskabets russiske samarbejdspartner, IBC Generium,...
Affitech A/S finanskalender for 2012
December 28, 2011 05:33 ET
|
Affitech A/S
København og Oslo, 2011-12-28 11:33 CET (GLOBE NEWSWIRE) --
Finanskalenderen for Affitech A/S, (NASDAQ OMX: AFFI) for 2012 er som følger:
29. marts 2012...
Affitech A/S financial calendar for 2012
December 28, 2011 05:33 ET
|
Affitech A/S
Copenhagen and Oslo, 2011-12-28 11:33 CET (GLOBE NEWSWIRE) --
The financial calendar for Affitech A/S, (NASDAQ OMX: AFFI) for 2012 is as follows
29th March,...
Affitech A/S modtager 2 millioner euro i licensbetaling for AT008 anti-CCR4 antistofprogram
November 28, 2011 07:27 ET
|
Affitech A/S
København og Oslo, 28 november, 2011, 2011-11-28 13:27 CET (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), der udvikler antistoflægemidler, meddeler i dag, at IBC Generium har indløst licensen...
Affitech A/S receives EUR 2 million license fee for AT008 anti-CCR4 antibody program
November 28, 2011 07:27 ET
|
Affitech A/S
Copenhagen and Oslo, 28 November, 2011, 2011-11-28 13:27 CET (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today that IBC Generium has exercised the...
Affitech A/S reports research & development progress and financial results for the third quarter of 2011
November 24, 2011 14:05 ET
|
Affitech A/S
Copenhagen and Oslo, 24th November, 2011, 2011-11-24 20:05 CET (GLOBE NEWSWIRE) --
Completion of preclinical development of anti-VEGF antibody AT001/r84
Anti-CCR4 antibody selected as first...
Affitech A/S annoncerer fremgang i forskning og udvikling og resultat for 3. kvartal 2011
November 24, 2011 14:05 ET
|
Affitech A/S
København og Oslo, 24. november 2011, 2011-11-24 20:05 CET (GLOBE NEWSWIRE) --
Præklinisk udvikling af anti-VEGF antistof AT001/r84 afsluttet
Anti-CCR4 antistof udvalgt som første...
Trans Nova Investments Limited makes a Voluntary Conditional Public Purchase Offer to the Shareholders of Affitech A/S and publishes Offer Document.
November 21, 2011 11:15 ET
|
Affitech A/S
On behalf of Trans Nova Investments Limited, an offer document is hereby made public regarding a voluntary conditional public purchase offer to the shareholders of Affitech A/S made as of today’s...
Trans Nova Investments Limited fremsætter frivilligt betinget offentligt købstilbud til aktionærerne i Affitech A/S og offentliggør tilbudsdokument.
November 21, 2011 11:15 ET
|
Affitech A/S
På vegne Trans Nova Investments Limited offentliggøres herved tilbudsdokument vedrørende frivilligt betinget offentligt købstilbud til aktionærerne i Affitech A/S, fremsat dags dato af Trans Nova...